OrphoMed, Inc. Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose in IBS-D Patients

SAN FRANCISCO--(BUSINESS WIRE)--OrphoMed, Inc. today announced positive results from the recent Phase 2 study of ORP-101 for treatment of IBS-D.

Click to view original post